| |||||||||

Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Operating Income | 315M | 6.50B | 8.22B | 8.09B | 9.14B | |||
| Gross Profit | 17.5B | 19.9B | 22.3B | 25.0B | 27.6B | |||
| Total Revenues | 21.4B | 23.9B | 26.5B | 29.6B | 31.6B | |||
| Net Income | 4.77B | 6.67B | 8.54B | 7.98B | 8.68B | |||
| Gross Margin | 75.8% | 77.6% | 79% | 78.3% | 79.1% | |||
| Research and Development Expense | 3.47B | 3.38B | 3.90B | 5.16B | 5.18B | |||
| R&D/Sales Ratio | 16.2% | 14.1% | 14.7% | 17.5% | 16.4% | |||
| Number of Patents | 0 | 0 | 0 | 0 | 0 | |||
| Number of Drugs in Phase I | 0 | 17.0 | 23.0 | 41.0 | 34.0 | |||
| Number of Drugs in Phase II | 0 | 15.0 | 20.0 | 20.0 | 31.0 | |||
| Number of Drugs in Phase III | 0 | 29.0 | 28.0 | 10.0 | 10.0 | |||
| Number of Drug Recalls | 0 | 0 | 21.0 | 39.0 | 12.0 | |||
| New Drug Applications | 0 | 25.0 | 21.0 | 0 | 0 | |||
| Revenue - Japan | 0 | 0 | 1.43B | 1.58B | 1.86B | |||
| ||||||